Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Hussein Abdul-Hassan Tawbi, Weiyi Peng, Denai Milton, Rodabe Navroze Amaria, Isabella Claudia Glitza, Wen-Jen Hwu, Sapna Pradyuman Patel, Michael K.K. Wong, Scott Eric Woodman, Cassian Yee, Jennifer Leigh McQuade, Michael T. Tetzlaff, Alexander J. Lazar, Suzanne Cain, Elizabeth M. Burton, Jan Hendrik Beumer, Patrick Hwu, Michael A. Davies
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890314705